Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies

David Miklos discusses recent advances in bispecific CAR-T therapy development.

The Scientist Creative Services Team in Collaboration with IsoPlexis
Sep 7, 2021

LIVE Webinar

Monday, September 27, 2021
2:30 - 3:30 PM Eastern Time

Register Now

Chimeric antigen receptor-T cell therapy targeting the surface receptor CD19 (CAR19) is a potent treatment option for patients with relapsed or chemotherapy-refractory B cell malignancies. Unfortunately, cancer continues to progress in a large subset of these patients due to changes in CD19-presentation on the cancer cells. To eliminate malignant B cells with low CD19 levels, researchers have developed CAR therapies that target the B cell-specific cell surface molecule CD22. While sequential CAR therapy has shown limited success, scientists have now developed a bispecific CAR-T cell that simultaneously targets CD19 and CD22. In this webinar brought to you by IsoPlexis, David Miklos will discuss recent advances in bispecific CAR-T therapy development and critical functional biomarkers for characterizing CAR-T cell product quality.

Register Now

Meet the Speaker:

David Miklos, MD, PhD
Chief, Blood and Marrow Transplantation and Cellular Therapy
Clinical Director, Cancer Cell Therapy
Stanford University

October 2021

Number Sense

Researchers debate how animals perceive quantities


Sponsored Product Updates

Can Saliva Replace Blood for DNA Collection and Analysis?
Saliva offers a less invasive and more cost-effective alternative for abundant high-quality DNA collection.
Controlling Western Blot Quality and Compliance
Learn how to follow pharmaceutical industry regulations when performing western blot experiments from start to finish.
Charting a Path to Clean Laboratory Air
Are you working with pathogens or volatiles? Use this flowchart to determine what safety cabinet or fume hood is necessary for any experimental situation.